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Edited by Beat ImhofAbstract Hyperhomocysteinemia is a cardiovascular risk fac-
tor and may contribute to the pathogenesis of atherosclerosis
by altering endothelial functions. The mechanism of homocyste-
ine-induced cell adhesion has been here investigated using EA.hy
926 cells. Homocysteine induces a stereospeciﬁc, time- and dose-
dependent cell adhesion which is prevented by adenosine. The
dramatic increase of S-adenosylhomocysteine induced by adeno-
sine-2 0,3 0-dialdehyde does not cause cell adhesion, indicating that
no apparent relationship exists between this process and intracel-
lular S-adenosylhomocysteine content. Homocysteine-induced
cell adhesion is abolished by pre-treatment with adenosine-
2 0,3 0-dialdehyde, demonstrating that the adenosine depletion
caused by reversal of S-adenosylhomocysteine hydrolase reac-
tion is responsible for homocysteine-induced cell damage.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Homocysteine; Homocysteine-induced cell
adhesion; EA.hy 926 cells; S-Adenosylhomocysteine;
S-adenosylhomocysteine hydrolase; Adenosine1. Introduction
Several lines of evidence from biochemical and epidemiolog-
ical studies indicate that mild hyperhomocysteinemia, which is
quite prevalent in a general population, is an independent risk
factor for stroke, cardiovascular and neurodegenerative dis-
eases and even enhances the risk associated with the conven-
tional risk factors [1–4]. Severe hyperhomocysteinemia, on
the other hand, is prevalently found in patients with rare genet-
ic disorders or renal impairment [1–4]. In any case, total plas-
ma homocysteine (Hcy) can be considered an eﬀective marker
of cardiovascular disease.
The toxic eﬀects of Hcy can be ascribed either to Hcy itself
or to changes in related metabolites caused by elevated Hcy
levels. In the ﬁrst case, the oxidation of Hcy leads to the pro-
duction of reactive oxygen radicals thus inducing an oxidative
stress [2–4]. Hcy can also induce oxidative stress through a
mechanism involving the targeting of antioxidant defenseAbbreviations: Hcy, homocysteine; Ado, adenosine; AdoMet,
S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; ADA,
adenosine-2 0,30-dialdehyde; BCECF-AM, 20,70-bis-(2-carboxyethyl)-
5-(and-6)-carboxy-ﬂuorescein acetoxymethyl ester
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isomerase [5]. In addition, the conversion of Hcy to Hcy thio-
lactone and the consequent N-homocysteinylation of proteins
may also play a relevant role in cardiovascular disease. In fact,
Hcy-containing proteins are toxic and induce an autoimmune
response which is associated with atherosclerosis in humans
[6].
The second hypothesis ascribes Hcy toxicity to its related
metabolites. Several studies have provided evidence that S-
adenosylhomocysteine (AdoHcy), the metabolic precursor of
Hcy, plays an important role in the vascular complications
of hyperhomocysteinemia [7–9]. In hyperhomocysteinemia, in
fact, the equilibrium of AdoHcy hydrolase reaction is shifted
toward the synthesis of AdoHcy, a potent inhibitor of most
S-adenosylmethionine (AdoMet)-dependent methyltransferas-
es [8,10]. The relation between Hcy and hypomethylation has
become a topic of utmost interest because the hypomethylation
of many tissue components, including proteins, DNA, RNA,
phospholipids, and small molecules, is one important mecha-
nism by which Hcy may be cytotoxic [10]. In this respect a
cause-control study showed that plasma AdoHcy concentra-
tion was a better predictor of cardiovascular diseases than
plasma homocysteine [7].
It has also been recently hypothesized that in hyperhomo-
cysteinemia the Hcy-induced reversal of AdoHcy hydrolase
reaction causes the increase of the intracellular formation of
AdoHcy at expense of free intracellular adenosine (Ado). This
event results in a lowering of extracellular Ado, a potent car-
dio- and vaso-protective nucleoside [11,12].
It is well known that a key event associated with hyperhom-
ocysteinemia is the induction of endothelial dysfunction which
is implicated in the pathophysiology of diﬀerent forms of car-
diovascular diseases [1–4,13]. Moreover, the process of cell
adhesion has been suggested to be an important step in the ini-
tiation and development of inﬂammatory processes associated
with atherosclerosis [13].
To examine the eﬀect of elevated Hcy levels in the endothe-
lial dysfunction, and to investigate the mechanism of Hcy-
induced cell adhesion, we have utilized EA.hy 926 cells as
model system [14], and adenosine-2 0,3 0-dialdehyde (ADA), a
potent irreversible AdoHcy hydrolase inhibitor [15].2. Materials and methods
2.1. Materials
D,L-Hcy and L-Hcy thiolactone hydrochloride, L-cysteine, ADA,
Ado, AdoHcy, catechol O-methyltransferase, recombinant human
tumor necrosis factor (TNFa), L-glutammine, penicillin–streptomycinblished by Elsevier B.V. All rights reserved.
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oxymethyl ester (BCECF-AM), and heptane sulfonic acid were pur-
chased from Sigma. Cell culture media (DMEM, RPMI-1640) and
Fetal Bovine Serum (FBS) were from Gibco BRL. Black 96-well assay
plates were from Microtech.
EA.hy 926 cells were a gift from Prof. Franco Dammacco, Depart-
ment of Biomedical Sciences and Human Oncology, University of
Bari. Human monocytic cells U937 used for adhesion assay were from
American Type Culture Collection.
2.2. Fluorescent labelling of U937 cells
For quantitative cell adhesion assays, U937 cells (4 · 106 cells/mL)
were ﬂuorescently labelled by incubation with 5 lM BCECF-AM in
RPMI-1640 medium for 30 min at 37 C. After incubation, the cells
were washed twice with 1% FBS/PBS to remove non-incorporated
dye and resuspended in DMEM medium at a density of 25 · 104
cells/mL.
2.3. Hcy treatment and cell adhesion assay
L-Hcy was freshly prepared from its thiolactone [16] and the ﬁnal
thiol concentration was determined spectrophotometrically using Ell-
man’s reagent [17]. EA.hy 926 cells were cultured to conﬂuence in a
96-well plate (17 · 103/well) and treated with varying concentrations
of Hcy, and with Ado, ADA and the respective positive (TNFa
10 ng/mL) and negative (plain medium) controls for the indicated peri-
ods of time. Following homocysteine treatment, EA.hy 926 cells were
co-incubated with BCEF-labelled U937 cells and cell adhesion was car-
ried out according to [18]. The ﬂuorescence intensity of each well was
measured using a ﬂuorescence multi-well plate reader (VICTOR3, Per-
kin–Elmer) set at excitation and emission wavelengths of 485 and
535 nm, respectively. Labelled U937 cells were used for a ﬂuorescence
standard curve.
2.4. Preparation of cell extracts and HPLC determination of AdoMet
and AdoHcy
EA.hy 926 cells were grown in 75 cm2 culture ﬂasks until conﬂuence.
After the removal of the culture medium, fresh medium either without
(control) or additioned with Hcy, ADA or Ado was added. The cells
were cultured at 37 C for 24 h and then trypsinized and counted. Cell
viability at the end of the treatment was >95% by trypan blue exclu-
sion. EA.hy 926 cells were harvested by centrifugation at 1100 rpm
for 5 min, and resuspended in 0.2 mL of 2% perchloric acid on ice
for 10 min. After centrifugation at 13000 · g for 20 min, the deprote-Fig. 1. Dose- and time-dependent eﬀect of L-Hcy on monocyte-endothelial ce
and in the presence of increasing concentrations of L-Hcy at 37 C for 24 h
positive control. (B) Time course for 100 lM L-Hcy. Data are the means +
*P < 0.05, **P < 0.01 compared to untreated cells.inized supernatant was neutralized with 0.2 M KOH on ice, centri-
fuged and analyzed by HPLC for determination of AdoMet and
AdoHcy. The pellet was solubilized with NaOH 0.1N and 2% Na2CO3
and then analyzed for protein concentration.
Separation of AdoMet and AdoHcy was performed by reverse-
phase C-18 column (5 lM particle size, 4.6 · 250 mm, Dionex) using
an Agilent 1100 series chromatograph. The elution was carried out
with a 15:85 (v/v) mixture of anhydrous methanol and 40 mM ammo-
nium phosphate containing 6 mM heptane sulfonic acid, pH 3.6 at a
ﬂow rate of 1 mL/min. The concentration of the compounds was deter-
mined by comparison of absorbance integrated peak areas with stan-
dard curves of AdoMet and AdoHcy. Yield determined by the
addition of methyl-14C-labeled AdoMet to deproteinized cell homoge-
nate was 95%.
The purity of the identiﬁed AdoMet and AdoHcy was checked by
the ‘‘enzymatic peak shift’’ utilizing adenosine deaminase from A. ory-
zae and cathecol O-methyltransferase for the identiﬁcation of AdoHcy
[19] and AdoMet [20] respectively. Following this procedure, aliquots
of neutralized cell extract were incubated for 60 min at 37 C with the
selected enzyme before the HPLC analysis. The chromatogram of the
resulting mixtures shows the absence of the UV-absorbing material at
the retention times corresponding to AdoHcy (28.7 min) or AdoMet
(21.4 min) and the simultaneous appearance of new peaks with the elu-
tion times corresponding to that of S-inosylhomocysteine (4.3 min)
and AdoHcy, respectively.
2.5. Statistical analysis
Data were expressed as means ± S.D. Statistical analysis was per-
formed using Student’s t-test. A P-value < 0.05 was considered statis-
tically signiﬁcant.3. Results and discussion
3.1. Hcy-induced cell adhesion
There is considerable evidence that the modulation of
immune-endothelial cells interaction is a potential mechanism
by which Hcy may contribute to the pathogenesis of athero-
sclerosis [1–4]. In this study we examined the eﬀect of Hcy
on endothelial cell adhesion. As reported in Fig. 1A, incuba-
tion of EA.hy 926 cells for 24 h with increasing concentrationll adhesion. (A) EA.hy 926 cells were incubated in the absence (control)
and U937 cell adhesion was measured. TNFa (10 ng/mL) was used as
S.D. of three separate experiments, each performed in quadruplicate.
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thelial cell adhesion up to 5.5-fold and appears of the same
order of magnitude of that observed in the presence of TNFa.
Moreover, Hcy-induced cell adhesion is time-dependent and
reaches a plateau after 6 h (Fig. 1B). The eﬀect of Hcy appears
stereospeciﬁc since the incubation with D,L-Hcy leads, at all
concentrations assayed, to only 50% cell adhesion with respect
to L-Hcy. Moreover, the speciﬁcity of this interaction is con-
ﬁrmed by the lack of any appreciable eﬀect of L-cysteine up
to 200 lM concentration (data not shown). These results are
in agreement with those reported elsewhere utilizing either
the same experimental system [21] or human umbilical vein
endothelial cells (HUVEC) [22,23] and human aortic endothe-
lial cells HAEC [18].
3.2. Hcy-induced cell adhesion is not mediated by AdoHcy
Despite increasing clinical evidence supporting the view that
Hcy is an atherogenic risk factor, the underlying mechanism of
Hcy-induced cell adhesion remains not completely elucidated
up to now.
It has been reported that hyperhomocisteinemia is associ-
ated with signiﬁcant increase in plasma and intracellular Ado-
Hcy with a consequent feed-back inhibition of AdoMet-
dependent methyltransferases [7,8,24,25]. AdoMet/AdoHcy
ratio is therefore considered an indicator of cellular ‘‘methyla-
tion potential’’ [10].
To study if Hcy-induced cell adhesion is dependent on
increased AdoHcy levels, with a consequent modiﬁcation of
AdoMet/AdoHcy ratio, we measured the intracellular AdoHcy
and AdoMet concentration after 24 h incubation of EA.hy 926
cells with increasing Hcy concentrations. The method
employed for separation and analysis of the two compounds,
that couples reversed-phase HPLC and ‘‘enzymatic peak
shift’’, allowed a rapid and unambiguous determination of
AdoHcy and AdoMet in the cell-free extract.
After Hcy treatment, the values of either AdoHcy and Ado-
Met concentration or AdoMet/AdoHcy ratio appear almost
unmodiﬁed with respect to the control cells up to 200 lM
Hcy (Table 1), whereas, concomitantly, a signiﬁcant cell adhe-
sion is observable (Fig. 1A). In contrast with these results, it
has been reported that incubation of cultured endothelial cells
with 50 lM Hcy signiﬁcantly increases intracellular levels of
AdoHcy, lowers AdoMet/AdoHcy ratio by 6–8-fold, and
inhibits carboxymethylation of P21ras playing a role on arterio-
sclerotic lesion formation [24]. It has to be noted, in this re-Table 1
Intracellular AdoMet and AdoHcy concentrationa and AdoMet/
AdoHcy ratio in EA.hy 926 cells
AdoMet · 102
(nmol/mg
protein)
AdoHcy · 102
(nmol/mg
protein)
[AdoMet]/
[AdoHcy]
ratio
Control 67 ± 3 2.0 ± 0.1 33.5
L-Hcy 100 lM 76 ± 4 2.3 ± 0.1 33.0
L-Hcy 200 lM 76 ± 4 2.5 ± 0.1 30.4
L-Hcy 500 lM 75 ± 4 3.8 ± 0.2 19.7
ADA 5 lM 78 ± 4 73.5 ± 4 1.06
L-Hcy 100 lM +
Ado 10 lM
77 ± 4 2.1 ± 0.1 36.6
L-Hcy 100 lM +
ADA 5 lM
76 ± 4 74.6 ± 4 1.02
aValues are means ± S.D.spect, that in the experimental protocol utilized, the medium
contained, in addition to Hcy, also Ado (50 lM) and an
Ado deaminase inhibitor added to prolong the extreme short
half life of Ado in culture, suggesting that the increase of Ado-
Hcy levels should be ascribed to the co-presence of Hcy and
Ado.
To further conﬁrm that cell adhesion is not related to in-
creased intracellular AdoHcy, we induced intracellular accu-
mulation of the thioether by incubation for 24 h with 5 lM
ADA, a AdoHcy hydrolase inhibitor that has been recently
utilized to evaluate in cultured endothelial cells the eﬀect of
AdoHcy accumulation on global genomic DNA methylation
status [9].
After the treatment with ADA, intracellular AdoHcy in-
creased about 35-fold with respect to the control (Table 1)
whereas, concomitantly, no cell adhesion was observable
(Fig. 2). These results indicate that in our experimental system,
no apparent relationship exists between intracellular AdoHcy
content or AdoMet/AdoHcy ratio and Hcy-induced cell adhe-
sion. These results are in agreement with those reported by
Doshi et al. [26] indicating that methylation status is not a
determinant of endothelial function during acute experimental
hyperhomocysteinemia.
3.3. Hcy-induced cell adhesion depends on Ado depauperation
As suggested by recent studies, Ado plays a role in the path-
ogenesis of the vascular complications of hyperhomocystein-
emia [11,12]. To verify this hypothesis, we incubated EA.hy
926 cells with 100 lM L-Hcy and 10 lM adenosine for 24 h
at 37 C. As shown in Fig. 2, the presence of the nucleoside
completely prevents monocyte-adhesion induced by 100 lM
Hcy, clearly indicating that Ado is involved in this process.Fig. 2. Eﬀect of Ado and ADA on L-Hcy-induced monocyte-
endothelial cell adhesion. EA.hy 926 cells were incubated at 37 C
for 24 h in the absence (control) and in the presence of the compounds
shown, and U937 cell adhesion was measured. Data are the
means + S.D. of three separate experiments, each performed in
quadruplicate. **P < 0.01 compared to untreated cells.
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prevents neutrophil adhesion to human endothelial cells after
hypoxia/reoxygenation [27]. Our results also show that no
appreciable increase in AdoHcy concentrations or in Ado-
Met/AdoHcy ratio is observable in these conditions (Table 1).
Endogenous Ado rather than a physiological modulator of
the cardiovascular function has to be considered as a ‘‘retalia-
tory metabolite’’ i.e. a molecule that is released in response to a
variety of dangerous stimuli to protect the organ systems in an
autocrine fashion [11]. It is reported that extracellular Ado ex-
erts a variety of physiological eﬀects in the heart and vessels
through the interaction with speciﬁc receptors and that the
perturbation of Ado-receptor system may play a role in spe-
ciﬁc diseases such as atherosclerosis, thrombosis, ischemia-
riperfusion injury and hyperhomocysteinemia [11,28].
To elucidate the role exerted by adenosine on Hcy-induced
cell adhesion, we incubated EA.hy 926 cells with 5 lM ADA
for 2 h to obtain a complete inhibition of AdoHcy hydrolase.
Then, 100 lM Hcy was added and the incubation was pro-
longed for 22 h. As shown in Fig. 2, no cell adhesion was ob-
servable. These results indicate that the inhibition of AdoHcy
hydrolase hampers Hcy-induced cellular uptake of Ado conse-
quent to the utilization of intracellular Ado through the rever-
sal of AdoHcy hydrolase reaction. In fact, AdoHcy hydrolase
inhibition allows to keep unchanged extracellular Ado needed
for Ado receptor stimulation.
This is the ﬁrst experimental evidence that the lowering of
intracellular Ado concentration in hyperhomocysteinemia is
directly responsible for Hcy-induced EA.hy 926 cell adhesion.
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